Tag: CF-MEV-107

Esperite (ESP) with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of Bronchopulmonary Dysplasia.

February 27, 2019 Group News
Tags
, , , , , , , , ,

CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory

Amsterdam, The Netherlands – 27 February 2019
read more

Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

November 29, 2018 Group News
Tags
, , , , , , , , , , , ,

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn’s, Bronchopulmonary dysplasia, Epilepsy and Stroke

Amsterdam, The Netherlands – 29 November 2018
read more